These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 36773747)

  • 1. Influence of P-glycoprotein on pulmonary disposition of the model substrate [
    Mairinger S; Hernández-Lozano I; Filip T; Löbsch M; Stanek J; Zeitlinger M; Hacker M; Tournier N; Wanek T; Ehrhardt C; Langer O
    Eur J Pharm Sci; 2023 Apr; 183():106404. PubMed ID: 36773747
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET imaging to assess the impact of P-glycoprotein on pulmonary drug delivery in rats.
    Hernández-Lozano I; Mairinger S; Filip T; Sauberer M; Wanek T; Stanek J; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Feb; 342():44-52. PubMed ID: 34971693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of P-gp and BCRP on pulmonary drug disposition assessed by PET imaging in rats.
    Mairinger S; Hernández-Lozano I; Filip T; Sauberer M; Löbsch M; Stanek J; Wanek T; Sake JA; Pekar T; Ehrhardt C; Langer O
    J Control Release; 2022 Sep; 349():109-117. PubMed ID: 35798092
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Factors Governing P-Glycoprotein-Mediated Drug-Drug Interactions at the Blood-Brain Barrier Measured with Positron Emission Tomography.
    Wanek T; Römermann K; Mairinger S; Stanek J; Sauberer M; Filip T; Traxl A; Kuntner C; Pahnke J; Bauer F; Erker T; Löscher W; Müller M; Langer O
    Mol Pharm; 2015 Sep; 12(9):3214-25. PubMed ID: 26202880
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [
    Mairinger S; Leterrier S; Filip T; Löbsch M; Pahnke J; Hernández-Lozano I; Stanek J; Tournier N; Zeitlinger M; Hacker M; Langer O; Wanek T
    J Cereb Blood Flow Metab; 2024 Jan; 44(1):142-152. PubMed ID: 37728771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Performance and Sensitivity of [
    Hernández-Lozano I; Leterrier S; Mairinger S; Stanek J; Zacher AS; Breyer L; Hacker M; Zeitlinger M; Pahnke J; Tournier N; Wanek T; Langer O
    Mol Pharm; 2024 Feb; 21(2):932-943. PubMed ID: 38225758
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative vulnerability of PET radioligands to partial inhibition of P-glycoprotein at the blood-brain barrier: A criterion of choice?
    Breuil L; Marie S; Goutal S; Auvity S; Truillet C; Saba W; Langer O; Caillé F; Tournier N
    J Cereb Blood Flow Metab; 2022 Jan; 42(1):175-185. PubMed ID: 34496661
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Parametric Imaging of P-Glycoprotein Function at the Blood-Brain Barrier Using k
    Breuil L; El Biali M; Vodovar D; Marie S; Auvity S; Bauer M; Goutal S; Rodrigo S; Langer O; Tournier N
    Mol Imaging Biol; 2023 Dec; 25(6):1135-1141. PubMed ID: 37801196
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Imaging the impact of blood-brain barrier disruption induced by focused ultrasound on P-glycoprotein function.
    Goutal S; Novell A; Leterrier S; Breuil L; Selingue E; Gerstenmayer M; Marie S; Saubaméa B; Caillé F; Langer O; Truillet C; Larrat B; Tournier N
    J Control Release; 2023 Sep; 361():483-492. PubMed ID: 37562557
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Increased permeability-glycoprotein inhibition at the human blood-brain barrier can be safely achieved by performing PET during peak plasma concentrations of tariquidar.
    Kreisl WC; Bhatia R; Morse CL; Woock AE; Zoghbi SS; Shetty HU; Pike VW; Innis RB
    J Nucl Med; 2015 Jan; 56(1):82-7. PubMed ID: 25500831
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron Emission Tomography Imaging Reveals an Importance of Saturable Liver Uptake Transport for the Pharmacokinetics of Metoclopramide.
    Caillé F; Goutal S; Marie S; Auvity S; Cisternino S; Kuhnast B; Pottier G; Tournier N
    Contrast Media Mol Imaging; 2018; 2018():7310146. PubMed ID: 29853808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. P-Glycoprotein (ABCB1) Inhibits the Influx and Increases the Efflux of
    Auvity S; Caillé F; Marie S; Wimberley C; Bauer M; Langer O; Buvat I; Goutal S; Tournier N
    J Nucl Med; 2018 Oct; 59(10):1609-1615. PubMed ID: 29748235
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dose-response assessment of tariquidar and elacridar and regional quantification of P-glycoprotein inhibition at the rat blood-brain barrier using (R)-[(11)C]verapamil PET.
    Kuntner C; Bankstahl JP; Bankstahl M; Stanek J; Wanek T; Stundner G; Karch R; Brauner R; Meier M; Ding X; Müller M; Löscher W; Langer O
    Eur J Nucl Med Mol Imaging; 2010 May; 37(5):942-53. PubMed ID: 20016890
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Tariquidar-induced P-glycoprotein inhibition at the rat blood-brain barrier studied with (R)-11C-verapamil and PET.
    Bankstahl JP; Kuntner C; Abrahim A; Karch R; Stanek J; Wanek T; Wadsak W; Kletter K; Müller M; Löscher W; Langer O
    J Nucl Med; 2008 Aug; 49(8):1328-35. PubMed ID: 18632828
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pilot study to assess the efficacy of tariquidar to inhibit P-glycoprotein at the human blood-brain barrier with (R)-11C-verapamil and PET.
    Wagner CC; Bauer M; Karch R; Feurstein T; Kopp S; Chiba P; Kletter K; Löscher W; Müller M; Zeitlinger M; Langer O
    J Nucl Med; 2009 Dec; 50(12):1954-61. PubMed ID: 19910428
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic Modeling of (
    García-Varela L; García DV; Kakiuchi T; Ohba H; Nishiyama S; Tago T; Elsinga PH; Tsukada H; Colabufo NA; Dierckx RAJO; van Waarde A; Toyohara J; Boellaard R; Luurtsema G
    Mol Pharm; 2021 Jan; 18(1):416-428. PubMed ID: 33315404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. P-glycoprotein function at the blood-brain barrier in humans can be quantified with the substrate radiotracer 11C-N-desmethyl-loperamide.
    Kreisl WC; Liow JS; Kimura N; Seneca N; Zoghbi SS; Morse CL; Herscovitch P; Pike VW; Innis RB
    J Nucl Med; 2010 Apr; 51(4):559-66. PubMed ID: 20237038
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Imaging the Impact of the P-Glycoprotein (ABCB1) Function on the Brain Kinetics of Metoclopramide.
    Pottier G; Marie S; Goutal S; Auvity S; Peyronneau MA; Stute S; Boisgard R; Dollé F; Buvat I; Caillé F; Tournier N
    J Nucl Med; 2016 Feb; 57(2):309-14. PubMed ID: 26585058
    [TBL] [Abstract][Full Text] [Related]  

  • 19. (R)-[11C]verapamil PET studies to assess changes in P-glycoprotein expression and functionality in rat blood-brain barrier after exposure to kainate-induced status epilepticus.
    Syvänen S; Luurtsema G; Molthoff CF; Windhorst AD; Huisman MC; Lammertsma AA; Voskuyl RA; de Lange EC
    BMC Med Imaging; 2011 Jan; 11():1. PubMed ID: 21199574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. (R)-[(11)C]verapamil is selectively transported by murine and human P-glycoprotein at the blood-brain barrier, and not by MRP1 and BCRP.
    Römermann K; Wanek T; Bankstahl M; Bankstahl JP; Fedrowitz M; Müller M; Löscher W; Kuntner C; Langer O
    Nucl Med Biol; 2013 Oct; 40(7):873-8. PubMed ID: 23845421
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.